Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

Inclusion Criteria:

All subjects must satisfy ALL of the following criteria at study entry:

- Subjects whom the investigator believes that they and/or their parent(s)/Legally
Acceptable Representative(s) can and will comply with the requirements of the
protocol.

- A male or female between, and including, 10 and 25 years of age at the time of the
vaccination.

- Written informed consent obtained from the subject/from the parent or Legally
Acceptable Representative(s) of the subject. Assent will be obtained from subjects who
are still legally minors in line with local rules and regulations.

- Healthy subjects as established by medical history and clinical examination before
entering into the study.

- Previously completed routine childhood vaccinations to the best of subject's/Legally
Acceptable Representative(s)'s knowledge.

- Female subjects of non-childbearing potential may be enrolled in the study.

- Female subjects of childbearing potential may be enrolled in the study, if the
subject:

- has practiced adequate contraception for 30 days prior to vaccination, and

- has a negative pregnancy test on the day of vaccination, and

- has agreed to continue adequate contraception for 2 months after vaccination.

Exclusion Criteria:

The following criteria should be checked at the time of study entry. If ANY exclusion
criterion applies, the subject must not be included in the study:

- Use of any investigational or non-registered product other than the study vaccine(s)
within 30 days preceding the dose of study vaccine, or planned use during the study
period.

- Chronic administration (defined as more than 14 days) of immunosuppressants or other
immune-modifying drugs within six months prior to vaccination. (For corticosteroids,
this will mean prednisone <10 mg/day, or equivalent, is allowed. Inhaled and topical
steroids are allowed.)

- Planned administration/administration of a vaccine not foreseen by the study protocol
within one month of the dose of vaccine, with the exception of any licensed
inactivated influenza vaccine.

- Previous vaccination with meningococcal polysaccharide or conjugate vaccine.

- Previous vaccination with vaccine components within the last month.

- History of meningococcal disease.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, including
human immunodeficiency virus infection, based on medical history and physical
examination.

- A family history of congenital or hereditary immunodeficiency, until the immune
competence of the potential vaccine recipient is demonstrated.

- History of allergic reactions or disease likely to be exacerbated by any component of
either vaccine, or by dry natural rubber latex.

- History of any neurologic disorders, including Guillain-Barré Syndrome.

- Major congenital defects or serious chronic illness.

- Acute disease at the time of enrollment.

- Administration of immunoglobulins and/or any blood products within the three months
preceding the dose of study vaccine or planned administration during the study period.

- Pregnant or lactating female.

- History of chronic alcohol consumption and/or drug abuse.

- Female planning to become pregnant or planning to discontinue contraceptive
precautions.

- Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy.

- Child in care.

- Concurrently participating in another clinical study, at any time during the study
period, in which the subject has been or will be exposed to an investigational or a
non-investigational product.